RAPIDe-3 In partnership with about 75 other institutions across the globe, the practice of Dr. Raffi Tachdjian is currently participating in the RAPIDe-3 study on hereditary angioedema (HAE) type 1 and type 2. The purpose of this study is to evaluate the efficacy and safety of an oral investigational drug,…
Sponsored Content
Recent Posts
- In life with angioedema, sometimes we just aren’t prepared to ‘take the win’
- HAE Day supporters hope to end years of diagnostic uncertainty
- From foot races to lit landmarks, HAE Day on May 16 aims to raise awareness
- Combined use of deucrictibant formulations in HAE expected to be safe
- HAE attacks drop with infrequent navenibart dosing in early trial